India’s largest life sciences entrepreneurship competition opens applications for startups, innovators and student teams nationwide
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Subscribe To Our Newsletter & Stay Updated
